moricizine
Trade name: ethmozine
Small moleculeapproved
Approved
Jun 19, 1990
Moricizine is an antiarrhythmic agent previously marketed as Ethmozine. It was used for prophylaxis and treatment of serious and life-threatening ventricular arrhythmias. In 2007 it was withdrawn and discontinued for commercial reasons. Moricizine can be administered intravenously but was more commonly provided as an oral formulation. — NCATS
Clinical trial activity
3 trials · 15 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 1982 (NCT00000504)
Timeline
Indications
Approved for
Mechanism of action
- Sodium channel alpha subunitBLOCKER
Sodium channel alpha subunit blocker
- Sodium channel protein type 1 subunit alpha (SCN1A) ↗
- Sodium channel protein type 5 subunit alpha (SCN5A) ↗
- Sodium channel protein type 4 subunit alpha (SCN4A) ↗
- Sodium channel protein type 7 subunit alpha (SCN7A) ↗
- Sodium channel protein type 2 subunit alpha (SCN2A) ↗
- Sodium channel protein type 9 subunit alpha (SCN9A) ↗
- Sodium channel protein type 3 subunit alpha (SCN3A) ↗
- Sodium channel protein type 11 subunit alpha (SCN11A) ↗
- Sodium channel protein type 8 subunit alpha (SCN8A) ↗
- Sodium channel protein type 10 subunit alpha (SCN10A) ↗
- Sodium channel protein type I alpha subunit
- Sodium channel protein type V alpha subunit
- Sodium channel protein type IV alpha subunit
- Sodium channel protein type VII alpha subunit
- Sodium channel protein type IX alpha subunit
- Sodium channel protein type II alpha subunit
- Sodium channel protein type III alpha subunit
- Sodium channel protein type XI alpha subunit
- Sodium channel protein type VIII alpha subunit
- Sodium channel protein type X alpha subunit
- Sodium channel alpha subunits; brain (Types I, II, III)
Approval history
- approvedPriority reviewJun 19, 1990
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2- Mol. weight
- 427.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL1075 ↗
- WikipediaMoracizine ↗
- NCATS2GT1D0TMX1 ↗
- ChEMBLCHEMBL1200334 ↗
Also known as
- [10-(3-morpholin-4-yl-propionyl)-10h-phenothiazin-2-yl]-carbamic acid ethyl ester
- [10-(3-morpholin-4-yl-propionyl)-10h-phenothiazin-2-yl]-carbamic acid ethyl ester
- en-313
- en-313
- en-313
- ethmozin
- ethmozin
- ethmozine
- ethmozine
- ethmozine
- ethmozine
- ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
- ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
- ethyl 10-(beta-n-morpholinylpropionyl)phenothiazine-2-carbamate
- ethyl 10-(beta-n-morpholinylpropionyl)phenothiazine-2-carbamate
- etmozin
- etmozin
- moracizin
- moracizin
- moracizina
- moracizina
- moracizine
- moracizine
- moracizine
- moracizine
- moracizine
- moracizine hydrochloride
- moracizine hydrochloride
- moracizinum
- moracizinum
- moricizine
- moricizine
- moricizine
- moricizine
- moricizine
- moricizine
- moricizine
- moricizine
- moricizine hcl
- moricizine hcl
- moricizine hcl
- moricizine hydrochloride
- moricizine hydrochloride
- moricizine hydrochloride
- moricizine hydrochloride
- moricizine hydrochloride
- moricizine hydrochloride
- moricizine hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000556 | Phase 3 | Mar 1, 1995 | National Heart, Lung, and Blood Institute (NHLBI), Statistics and Epidemiology Research Corporation |
| NCT00000526 | Phase 3 | Aug 1, 1986 | National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT00000504 | Phase 2 | Sep 1, 1982 | Baylor University, Clinical Data, Inc., Columbia University, Department of Veteran Affairs, Johns Hopkins University, Medical College of Virginia, National Heart, Lung, and Blood Institute (NHLBI), Rhode Island Hospital, Salt Lake Clinic Research Foundation, University of Alabama, Birmingham, University of Montreal, University of Rochester, Vanderbilt University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 3 | 3 | 2 | 1982 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Clinical Data, Inc. | For profit | 1 | 0 | 1 | 1982 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 1982 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Medical College of Virginia | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Rhode Island Hospital | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Salt Lake Clinic Research Foundation | Academic/Hospital | 1 | 0 | 1 | 1982 |
| Statistics and Epidemiology Research Corporation | Academic/Hospital | 1 | 0 | 1 | 1995 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 1982 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 1982 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 1982 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 1986 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 1982 |
15 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Shire | For profit | NDA | Jun 19, 1990 |